InvestorsHub Logo
Followers 5
Posts 480
Boards Moderated 0
Alias Born 05/01/2019

Re: kettleman post# 9554

Monday, 06/13/2022 10:48:06 AM

Monday, June 13, 2022 10:48:06 AM

Post# of 13843
Hello kettleman, the best I can offer you as an explanation is a Mar 2021 quote from….you guessed it: Me.

“At least you’re specifying GAUZE market this time.
Meaning you must adjust your $5.8 Billion sales # as well.
So, 25% of a 900 Million. $225 Million in POTENTIAL sales.
I’m not sure they’ll get a $2.5 B offer for $225 M sales.
Last year J&J offered $400 Million for Tachosil patch which has $155 m in yearly sales.
Fell through, but a realistic example. Real DD matters.

It was a follow up to Feb 2021 DD post:

“… if you truly know the market you would understand that gauze makes up less than 15% of the market. The majority belongs to injectables, sponges, spays, powders and gels.

It’s hard to take over 25% of the entire market when startOmg from 0. Nevertheless, when at this time only 15% of the market is available.

Yes I am aware of the current PRs stating patents have been filed and RD continues on other hemostyp products. “